Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults

The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.

Inclusion Criteria:

1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial
2. Physical examination and laboratory results without clinically significant findings
3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
4. Subjects must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during treatment and the 4-week F/U period after the last treatment.

Exclusion Criteria:

1. Use of any investigational or non-registered product (adjuvant, drug) other than CV8102 within 4 weeks preceding the administration of the CV8102, or planned use of any such agent during the trial period

2. Subject has received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine or planned vaccinations during the trial period

3. Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted

4. Any medically diagnosed or suspected immune deficient condition based on medical history and physical examination

5. History of autoimmune disease or suspected autoimmune disease based on medical history and physical examination that cannot be ruled out based on further examinations

6. Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of CV8102 or licensed rabies vaccine

7. Acute disease at the time of enrolment. Acute disease is defined as the presence of any acute condition including but not limited to non-febrile or febrile common colds, urinary tract infections, inflammatory, allergic or traumatic conditions that may interfere with safety assessment of the investigational products

8. Presence or evidence of significant acute or chronic disease, in particular heart disease including coronary artery disease and chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease [COPD]); uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease)

9. Major congenital defects

10. Known allergy to any component (or closely related substance) of the licensed rabies vaccine product

11. Known type I allergy to beta-lactam antibiotics

12. Evidence of current alcohol or drug abuse

13. History of any neurological disorders or seizures

14. Known seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV)

15. Foreseeable non-compliance with protocol as judged by the Investigator

16. History of any life-threatening anaphylactic reactions

17. Subjects with impaired coagulation in whom an IM injection is contraindicated.

    Additional exclusion criteria for subjects participating in the (adjuvanted) rabies vaccination part:

18. Subject has previously received any investigational or licensed rabies vaccine

19. Intending to travel to regions/countries for which rabies vaccinations are recommended or where high risk of infection exists according to travel recommendations by the German Society of Tropical Medicine and International Health (DTG) during the trial and F/U period

20. Subject is taking chloroquine for malaria treatment or prophylaxis.